Assessment of Cardiovascular Risk Factors in Patients with Type 2 Diabetes in Upper Egypt Villages

References

• Bianchi C, Miccoli R, Bonadonna RC, et al. Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology, and evolution of type 2 diabetes (GENFIEV) study. Nutr Metab Cardiovasc Dis. 2011;21:699–705. doi:10.1016/j.numecd.2010.03.006
   PubMedGoogle Scholar
• Shin JA, Lee JH, Lim SY, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013;4:334–343. doi:10.1111/jdi.12075
   PubMed Web of Science ®Google Scholar
• Bonadonna RC, Cucinotta D, Fedele D, et al. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diab Care. 2006;29:2701–2707.
   PubMed Web of Science ®Google Scholar
• Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl. 2):S14–S21. doi:10.1007/PL00002934
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853. doi:10.1016/S0140-6736(98)07019-6
   PubMed Web of Science ®Google Scholar
• Prattichizzo F, de Candia P, De Nigris V, et al. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism. 2020;110:154308. doi:10.1016/j.metabol.2020.154308
   PubMedGoogle Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2013;51(15):1512–1524. doi:10.1016/j.jacc.2008.02.034
   Google Scholar
• Buse JB, Ginsberg HN, Bakris GL, et al.; American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diab Care. 2007;30:162–172.
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393. doi:10.1056/NEJMoa021778
   PubMed Web of Science ®Google Scholar
• Reisin E, Harris RC, Rahman M. Commentary on the 2014 BP guidelines from the panel appointed to the eighth Joint National Committee (JNC 8). J Am Soc Nephrol. 2014;25(11):2419–2424.
   PubMedGoogle Scholar
• Kenneth FAS, Harris TB, et al. Overweight, Obesity, and Mortality in a Large Prospective Cohort of Persons 50 to 71 Years Old. N Engl J Med. 2006;355:763–778. doi:10.1056/NEJMoa055643
   PubMedGoogle Scholar
• American Diabetes Association: diagnosis and classification of diabetes mellitus. Diab Care. 2010;33:S62–S69. doi:10.2337/dc10-S062
   PubMedGoogle Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diab Care. 2016;39:717–725.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJA, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289. doi:10.1016/S0140-6736(05)67528-9
   PubMed Web of Science ®Google Scholar
• Prattichizzo F, La Sala L, Rydén L, et al. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol. 2019;26(2_suppl):73–80. doi:10.1177/2047487319880040
   PubMedGoogle Scholar
• Bogdan T, Oana A. The relationship between hemoglobin a1c and chronic complications in diabetes mellitus. Romanian J Diab Nutrition Metabolic Diseases. 2012;19:2.
   Google Scholar
• Bower JK, Appel LJ, Matsushita K, et al. Glycated hemoglobin and risk of hypertension in the atherosclerosis risk in communities study. Diab Care. 2012;35(5):1031‐1037. doi:10.2337/dc11-2248
   Google Scholar
• Britton KA, Pradhan AD, Michael Gaziano J, et al. Hemoglobin A1C, body mass index, and the risk of hypertension in women. Am J Hypertens. 2011;24(3):328–334. doi:10.1038/ajh.2010.233
   PubMed Web of Science ®Google Scholar
• He J, Klag MJ, Caballero B, et al. Plasma insulin levels and incidence of hypertension in African Americans and whites. Arch Intern Med. 1999;159:498–503. doi:10.1001/archinte.159.5.498
   PubMedGoogle Scholar
• Liese AD, Mayer-Davis EJ, Chambless LE, et al. Atherosclerosis risk in communities study investigators elevated fasting insulin predicts incident hypertension: the ARIC study. J Hypertens. 1999;17:1169–1177. doi:10.1097/00004872-199917080-00017
   PubMed Web of Science ®Google Scholar
• Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci. 2007;112:375–384. doi:10.1042/CS20060247
   PubMed Web of Science ®Google Scholar
• Imperatore G, Cadwell BL, Geiss L, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: national health and nutrition examination surveys, 1971–2000. Am J Epidemiol. 2004;160:531–539. doi:10.1093/aje/kwh232
   PubMed Web of Science ®Google Scholar
• Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120:212–220. doi:10.1161/CIRCULATIONAHA.108.846519
   PubMed Web of Science ®Google Scholar
• Power C, Thomas C. Changes in BMI, duration of overweight and obesity, and glucose metabolism: 45 years of follow-up of a birth cohort. Diab Care. 2011;34(9):1986–1991. doi:10.2337/dc10-1482
   PubMedGoogle Scholar
• Lipsky LM, Gee B, Liu A, et al. Glycemic control and variability in association with body mass index and body composition over 18months in youth with type 1 diabetes. Diabetes Res Clin Pract. 2016;120:97–103. doi:10.1016/j.diabres.2016.07.028
   PubMed Web of Science ®Google Scholar
• Wei GS, Coady SA, Reis JP, et al. Duration and degree of weight gain and incident diabetes in younger versus middle-aged black and white adults: ARIC, CARDIA, and the framingham heart study. Diab Care. 2015;38(11):2042‐2049. doi:10.2337/dc14-2770
   Google Scholar
• Yabe D, Type SY. 2 diabetes via beta-cell dysfunction in East Asian people. Lancet Diab Endocrinol. 2016;4:2–3. doi:10.1016/S2213-8587(15)00389-7
   PubMed Web of Science ®Google Scholar
• Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97. doi:10.1038/nri2921
   PubMed Web of Science ®Google Scholar
• Bodhe C, Jankar D, Bhutada T, et al. HbA1c: predictor of dyslipidemia and atherogenicity in diabetes mellitus. Int J Basic Med Sci Pharmacy June. 2012;2(1):25–27.
   Google Scholar
• Dubowitz N, Xue W, Long Q, et al. Aging is associated with increased HbAlc levels, independently of glucose levels and insulin resistance, and also with decreased HbAlc diagnostic specificity. Diabet Med. 2014;31:927–935. doi:10.1111/dme.12459
   PubMedGoogle Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet. 2009;373:1765–1772. doi:10.1016/S0140-6736(09)60697-8
   PubMed Web of Science ®Google Scholar
• Peng G, Lin M, Zhang K, et al. Hemoglobin A1c can identify more cardiovascular and metabolic risk profile in OGTT-negative chinese population. Int J Med Sci. 2013;10(8):1028–1034. doi:10.7150/ijms.5905
   PubMedGoogle Scholar
• Okosun I, Annor F, Dawodu E, et al. clustering of cardiometabolic risk factors and risk of elevated HbA1c in non-hispanic white, non-hispanic black, and mexican-American adults with type 2 diabetes. Diab Metab Syndrome. 2014;8:88–90. doi:10.1016/j.dsx.2014.04.026
   Google Scholar
• Lorbeer R, Empen K, Dorr M, et al. Association between glycosylated haemoglobin A (1c) and endothelial function in an adult non-diabetic population. Atherosclerosis. 2011;217:358–363. doi:10.1016/j.atherosclerosis.2011.04.007
   PubMed Web of Science ®Google Scholar
• Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006;55:1133–1140. doi:10.2337/diabetes.55.04.06.db05-1076
   PubMed Web of Science ®Google Scholar
• Zheng F, Lu W, Jia C, et al. Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation. Endocrine. 2010;37:201–208. doi:10.1007/s12020-009-9296-6
   PubMedGoogle Scholar
• Shah B, Sha D, Xie D, et al. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999–2004. Diab Care. 2012;35(5):1074–1078. doi:10.2337/dc11-1724
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, et al. effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591. doi:10.1056/NEJMoa0706245
   PubMed Web of Science ®Google Scholar